Clinical Trials Logo

Clinical Trial Summary

The goal of this study is to learn about the effect of heat and humidity on cognition and health. The main question[s] it aims to answer are: type of study: interventional participant population: 20-40years, both gender, healthy Participants will be exposed for 4 different sessions of 8 hours at a time, to 32˚ C or 25˚ C in combination with relative humidity of 30 %RH or 70 %RH.


Clinical Trial Description

Overall, the project aims to evaluate the effects of high vs. neutral temperature (32˚ C vs. 25˚ C) in combination with high vs. low humidity (30 %RH vs. 70 %RH) on cognition, for longer exposure duration (8 hours). Deviations from the personal comfort zones are expected to affect both subjective feelings and physiological parameters. Therefore, the following parameters will be included: cognition, environmental perception, energy expenditure, body temperatures. Main research question and primary objective: What is the impact of being exposed for 8 hours to a high humidity (RH 70%) versus low humidity (RH 30%) on cognitive performance of individuals if the room temperature is 25ºC or 32ºC? This leads to the following hypotheses: - Exposure to an indoor high relative humidity (RH 70%) at a warm temperature (32ºC) of a long duration (8 hours) reduces the composite score, speed and accuracy of cognitive performance compared to an exposure to a low RH (30%) at the same temperature (32ºC) due to the humidity. - An exposure to an indoor high relative humidity (RH 70%) at a neutral temperature (25ºC) of a long duration (8 hours) would reduce the composite score, speed and accuracy of cognitive performance compared to an exposure to a low RH (30%) at a neutral temperature (25 ºC) due to previous literature for humidity influences at neutral temperatures. Secondary research question and secondary objective: What is the effect of high vs. neutral temperature (32˚ C vs. 25˚ C) in combination with high vs. low humidity (30 %RH vs. 70 %RH) on physiological responses, environmental perception, decision making, and bias behaviour? This leads to the following hypotheses: 1. Does an 8 hour exposure to an elevated concentration of indoor humidity lead to an increase in energy expenditure and/or a greater difference in proximal and distal blood flow and skin temperature gradients compared to a lower indoor humidity for each of the temperature settings? 2. What are the effects of high humidity on substrate oxidation, blood pressure, heart rate variability, proximal and distal skin temperature, risk behavior and decision-making responses of individuals? 3. What are the effects of higher humidity on environmental perception (thermal, air quality, moisture/wetness) comfort, perception, and sensation? - An exposure to an indoor high relative humidity (RH 70%) at a warm temperature (32ºC) of a long duration (8 hours) reduces the composite score, speed and accuracy of cognitive performance compared to an exposure to a high RH (70%) at a neutral temperature (25 ºC) due to the humidity and temperature. - An exposure to an indoor low relative humidity (RH 30%) at a warm temperature (32ºC) of a long duration (8 hours) would reduce the composite score, speed and accuracy of cognitive performance compared to an exposure to the same low RH (30%) at a neutral temperature (25 ºC) due to the temperature. Exploratory research question and objective: What is the interaction effect of high vs. neutral temperature (32˚ C vs. 25˚ C) in combination with high vs. low humidity (30 %RH vs. 70 %RH) on cognitive performance, physiological responses, environmental perception, decision making, and bias behaviour? ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05972187
Study type Interventional
Source Maastricht University Medical Center
Contact Cynthia Ly, MSc
Phone +31644602337
Email C.ly@maastrichtunicersity.nl
Status Recruiting
Phase N/A
Start date June 18, 2023
Completion date June 1, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1